Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations
05 nov. 2018 16h01 HE
|
Dynavax Technologies Corporation
Conference Call to be held Today at 4:30pm ET/1:30pm PT BERKELEY, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the...
Dynavax to Host Third Quarter 2018 Financial Results Conference Call
29 oct. 2018 06h00 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the third quarter ended September 30,...
Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress
20 oct. 2018 08h45 HE
|
Dynavax Technologies Corporation
- 70% overall response rate (33/47 patients) at 2 mg dose of SD-101 includes 17 additional patients - -Progression free survival, response rate in patients with PDL-1 negative tumors and biomarker...
Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® (pembrolizumab) in the I-SPY 2 TRIAL For Breast Cancer
15 oct. 2018 06h00 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif. and SAN FRANCISCO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) and Quantum Leap Healthcare Collaborative™ (QLHC) announced today that the...
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress
09 oct. 2018 06h00 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating SD-101,...
Dynavax to Present at the 2018 Cantor Global Healthcare Conference
27 sept. 2018 16h01 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that Eddie Gray, Dynavax’s Chief Executive Officer, will present at the 2018...
Dynavax Announces Publication of Preclinical Study of TLR9 Agonist in Lung Cancer
04 sept. 2018 06h30 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced publication of a preclinical study demonstrating that inhalation of a TLR9...
Dynavax Announces Publication of Two Papers in Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101
28 août 2018 06h30 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that two peer-reviewed papers reporting clinical studies of SD-101 have been...
Dynavax Reports Second Quarter 2018 Financial Results
06 août 2018 16h01 HE
|
Dynavax Technologies Corporation
HEPLISAV-B® Launch Progressing as Planned with Key Customer Successes Three abstracts accepted for presentation at European Society for Medical Oncology (ESMO) 2018 Annual Meeting Conference Call to...
Dynavax to Host Second Quarter 2018 Financial Results Conference Call
30 juil. 2018 14h45 HE
|
Dynavax Technologies Corporation
BERKELEY, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the second quarter ended June 30, 2018...